On May 30, 2014 Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company’s common stock on a post-reverse split basis shall commence on Friday, June 6, 2014. The common stock will continue to trade under the symbol “INO.” Inovio Pharmaceuticals Inc (NYSEMKT:INO) weekly performance is 7.00%. On last trading day company shares ended up $2.14. Analysts mean target price for the company is $4.80. Inovio Pharmaceuticals Inc (NYSEMKT:INO) distance from 50-day simple moving average (SMA50) is -19.48%.
On May 29, Zeldes Haeggquist & Eck, LLP, a shareholder and consumer rights litigation firm has commenced an investigation into Prana Biotechnology Limited (ADR) (NASDAQ:PRAN). The investigation is related to potential violations of federal securities laws and other violations. Prana Biotechnology researches and develops therapeutic drugs for the treatment of neurological disorders. The Company’s product line includes PBT2, which is in Phase II clinical trials for the treatment of Alzheimer’s disease. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares fell -5.18% in last trading session and ended the day on $1.83. Its return on assets is -114.00%. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) quarterly performance is -83.09%.
On May 31, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. The results were presented in a poster, entitled “First-in-human Phase 1 dose-escalation study of AV-203, a monoclonal antibody against ErbB3 in patients with metastatic or advanced solid tumors” (Abstract #11113, Poster #395, S Hall A2), at the Tumor Biology General Poster Session of the American Society of Clinical Oncology 2014 Annual Meeting, taking place May 30 – June 3, 2014, in Chicago. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares moved down -1.80% in last trading session and was closed at $1.09, while trading in range of $1.06 – $1.19. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) year to date (YTD) performance is 1.87%.
On May 30, 2014 Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo’s zinc finger nuclease (ZFN) genome-editing technology in hematopoietic stem/progenitor cells (HSPCs). Sangamo Biosciences, Inc. (NASDAQ:SGMO) ended the last trading day at $12.30. Company weekly volatility is calculated as 5.08% and price to cash ratio as 3.92. Sangamo Biosciences, Inc. (NASDAQ:SGMO) showed a negative weekly performance of -6.89%.
On June 1, 2014 ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical Oncology (ASCO) annual meeting in Chicago. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) weekly performance is -12.21%. On last trading day company shares ended up $1.15. Analysts mean target price for the company is $5.69. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) distance from 50-day simple moving average (SMA50) is -6.91%.
Leave a Reply